Why Lundbeck stock moves
Lundbeck rose clearly without company news.
Written after the close on ·
Earnings report
Next report: November 11. On its last 15 report days Lundbeck usually moved about 3.3%. On a normal day it moves 1.1%.
August 19, 2026: −3.28%May 12, 2026: −1.75%February 4, 2026: −9.04%November 11, 2025: −4.52%
Why today
15,984 news analyzed todayLundbeck rose clearly without company news.
Over the last five trading days it rose clearly, in line with a strongly rising OMX Copenhagen 25.
The most likely drivers are the market's overall rally and buyers returning after a strong year.
Trading was thinner than usual, so the move may not be as firm.
The shares are near their highest close of the past year.
Today's move of +1.74% was 1.6 times a normal day's 1.1%. OMX Copenhagen 25 moved −0.23% on the same day.
Lundbeck +1.74%OMX Copenhagen 25 −0.23%Much stronger than the market
What analysts expect, and how often they have been right
Analysts’ estimates for Lundbeck.
Lundbeck earned more than expected in 6 out of 8 reports.
Not in the chart because no estimate and result are available: 2 of the 10 reports in this period, the latest on August 19, 2026.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 5 out of 8 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 56.00 DKK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedDKK
Next reported quarter: expected earnings per share of 1.50 DKK (November 11). For the current fiscal year, expected earnings per share changed from 6.33 DKK three months ago to 6.37 DKK now. 2026 estimate: 6.37 DKK. 2027 estimate: 6.16 DKK.
Has the share price followed the business?
Price and earnings moved in the same direction: 3 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed +4% and earnings per share +2%.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn DKK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn DKK
Price and earnings moved in the same direction: 3 out of 3 years.Market cap (Now): 55.6 bn DKKRevenue 2025: 24.6 bn DKK
What the key figures say about Lundbeck
The figures connect what Lundbeck earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: 1.93 DKK–3.22 DKK. Peers: Hims & Hers Health -$0.64, Swedish Orphan Biovitrum 18.94 SEK, Zoetis $5.88. 2026 estimate: 6.37 DKK (6.15 DKK–6.48 DKK). 2027 estimate: 6.16 DKK (5.80 DKK–6.41 DKK).
What the company sold during the year.
2022–2025: 18.2 bn DKK–24.6 bn DKK. Peers: Hims & Hers Health $2.6B, Swedish Orphan Biovitrum 32.0 bn SEK, Zoetis $9.5B. 2026 estimate: 26.0 bn DKK (25.8 bn DKK–26.2 bn DKK). 2027 estimate: 26.3 bn DKK (25.1 bn DKK–26.9 bn DKK).
The percentage of revenue left after the costs of running the business.
2022–2025: 14.9%–21.4%. Peers: Hims & Hers Health −6.0%, Swedish Orphan Biovitrum 29.8%, Zoetis 37.4%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: 9.2%–12.8%. Peers: Hims & Hers Health −32.0%, Swedish Orphan Biovitrum 16.3%, Zoetis 57.6%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 13.0–14.2. Peers: Swedish Orphan Biovitrum 26.3, Zoetis 13.5. 2026 estimate: 8.8. 2027 estimate: 9.1.
What investors pay for each unit the company sells.
2022–2025: 1.42–1.86. Peers: Hims & Hers Health 2.35, Swedish Orphan Biovitrum 5.42, Zoetis 3.40. 2026 estimate: 2.14. 2027 estimate: 2.11.
Money paid to shareholders per share, summed by calendar year.
2023–2025: 0.58 DKK–0.95 DKK.
The ordinary yearly dividend as a percentage of the share price.
2022–2025: 0.0%–2.2%. Peers: Hims & Hers Health 0.0%, Swedish Orphan Biovitrum 0.0%, Zoetis 2.7%.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -0.17–2.11. Peers: Swedish Orphan Biovitrum 1.18, Zoetis 1.92.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 1.24–1.72. Peers: Hims & Hers Health 18.72, Swedish Orphan Biovitrum 3.82, Zoetis 9.80.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 10.2–13.8.
Cash left after investments, divided by the number of shares.
2022–2025: 2.72 DKK–4.90 DKK. Peers: Hims & Hers Health $0.26, Swedish Orphan Biovitrum 18.69 SEK, Zoetis $5.61.
The percentage of assets financed by shareholders’ equity.
2022–2025: 43.4%–58.9%.
The dividend explained
A dividend is money paid to shareholders. Lundbeck paid 1.15 DKK per share in the twelve months through November 5, 2026.
On the ex-dividend day, March 19, 2026, Lundbeck traded without the right to the 1.15 DKK dividend. The price went from 38.00 DKK to 37.14 DKK; including the dividend, the day's change was +0.8%. Entitlement passes from the company to shareholders on the ex-day; payment comes later.
2023: 0.58 DKK2024: 0.70 DKK2025: 0.95 DKK2026 so far: 1.15 DKK
What to watch next, and why
The earnings report shows how Lundbeck's revenue and profit have changed.
- Earnings report
The earnings report shows how Lundbeck's revenue and profit have changed.
Add to calendar
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Lundbeck usually moved about 3.3%. On a normal day it moves 1.1%.
−3.28% −1.75% −9.04% −4.52%
10,000 DKK in Lundbeck bought on June 10, 2022 is worth 18,800 DKK today, with dividends reinvested.
The same amount in OMX Copenhagen with dividends would have become 11,800 DKK.
What would 10,000 DKK in Lundbeck be worth today? →
What would 10,000 DKK in Lundbeck be worth today?
18,800 DKK
with dividends reinvested, bought on June 10, 2022. The same amount in OMX Copenhagen with dividends would have become 11,800 DKK.
At worst it was worth 7,460 DKK (October 5, 2022).
The five biggest days of the journey
· −11.4% · the whole market rose 0.4% the same day · report day
· +10.5% · the whole market rose 1.5% the same day
· +10.3% · the whole market rose 0.5% the same day · report day
· +9.4% · the whole market fell 0.5% the same day · report day
· −9.0% · the whole market fell 2.2% the same day · report day
Earlier days
+2.66% market +1.75% Lundbeck rose clearly over the week, moving more than the OMX Copenhagen 25 index, which also rose clearly. Read →
Lundbeck rose clearly over the week, moving more than the OMX Copenhagen 25 index, which also rose clearly.
The rise likely came partly from SEB raising its price target, the fair share price it sees, to DKK 58 from 46 on Tuesday, while keeping its Hold rating, meaning it sees no clear reason to buy or sell.
Lundbeck's shares were also near their highest close of the past year, a sign of strong investor interest.
The main drag was the European Medicines Agency opening a safety review of Deanxit, a depression and anxiety drug, after reports of serious side effects, announced Friday and again Wednesday.
−0.45% market +1.82% Lundbeck fell slightly, while the market rose sharply. Read →
Lundbeck fell slightly, while the market rose sharply.
The move was an ordinary one for Lundbeck, within its usual daily range.
Over the last five trading days, Lundbeck rose clearly, moving in line with the market.
The move was small, and trading was well below its usual level, so it may not reflect a strong view.
+1.48% market +0.22% Lundbeck rose clearly, moving more than the market. Read →
Lundbeck rose clearly, moving more than the market.
The market index OMX Copenhagen 25 rose only slightly that day.
SEB raised its price target, the share price it sees as fair, to DKK 58 and kept its Hold rating.
Over the last five trading days, Lundbeck rose sharply, in line with a sharply rising market.
The move was big for Lundbeck, roughly twice a normal five-day stretch, and the stock sits near its one-year high.
−0.73% market +0.50% Lundbeck fell slightly, against a rising market. Read →
Lundbeck fell slightly, against a rising market.
Over the last five trading days Lundbeck rose clearly, moving in line with OMX Copenhagen 25, which also rose sharply.
The move was an ordinary one for Lundbeck, and trading volume was well above its usual level.
The review of Deanxit is the most likely reason for the dip, though the weekly rise came from broader gains.
+0.18% market +0.07% Lundbeck, Nasdaq Copenhagen, rose modestly with the market. Read →
Lundbeck, Nasdaq Copenhagen, rose modestly with the market.
Lundbeck was roughly unchanged in the last session, in line with a flat OMX Copenhagen 25.
Only the day's move was ordinary, so it was an ordinary day for Lundbeck.
Over the last five trading days Lundbeck rose sharply, matching the market's very sharp gain.
The European Medicines Agency is reviewing Deanxit, a depression and anxiety drug, after serious side effects were reported, news that came out after the session closed.
+4.70% market +4.94% Lundbeck rose sharply over the week, moving in line with the broader Danish market, which also rose very sharply. Read →
Lundbeck rose sharply over the week, moving in line with the broader Danish market, which also rose very sharply.
The strongest support came from DNB Carnegie raising its target price, the share price it sees as fair, while keeping its buy rating.
Analysts also pointed to a pivotal epilepsy data readout overshadowing the upcoming earnings report.
Healthcare stocks on the exchange rose over the same days, which helped the sector mood.
+3.13% market +0.30% Lundbeck rose without a company-news explanation. Read →
Lundbeck rose without a company-news explanation.
Over the last five trading days it rose sharply, in line with OMX Copenhagen 25, which also rose sharply.
The move was big for Lundbeck, about twice a normal five-day stretch, and similar moves happened roughly ten times in the past year.
Its latest close sits at the highest level of the past year, well above its February low.
The market's rise was partly driven by the healthcare sector, which rose only slightly, so Lundbeck's extra gain in the session is not explained by news.
+1.05% market +2.80% Lundbeck rose clearly without company news. Read →
Lundbeck rose clearly without company news.
Lundbeck rose clearly in the last session, but the market rose even more, so it lagged OMX Copenhagen 25.
Over the last five trading days Lundbeck rose sharply, well ahead of the market, and this was a big move for the stock.
No company news explains the last session's rise, so the likely reasons are the broad market and healthcare sector strength.
Watch the next earnings report on Wednesday 11 November 2026.
−0.38% market +0.57% Lundbeck was steady without a company-news explanation. Read →
Lundbeck was steady without a company-news explanation.
It fell slightly while the OMX Copenhagen 25 rose slightly, so it moved against the market.
Over the last five trading days, Lundbeck rose very sharply, well above the market's sharp gain.
The move was about three times a normal five-day stretch for Lundbeck, rare for the stock.
Board news, including a new chair, came earlier and does not explain the last session.
+0.67% market +1.34% Lundbeck rose slightly without a company-news explanation. Read →
Lundbeck rose slightly without a company-news explanation.
Over the last five trading days Lundbeck rose very sharply, far more than the market, which also rose sharply.
The move was very big for Lundbeck, the kind seen only once in the past year.
Lundbeck trades at its highest close of the past year, well above its early February low.
Trading volume was about twice a normal session, which suggests heavy interest.
+1.17% market −0.63% Lundbeck rose sharply, with no company news explaining it. Read →
Lundbeck rose sharply, with no company news explaining it.
In the same session, OMX Copenhagen 25 fell clearly, so Lundbeck moved against the market.
Over the last five trading days, Lundbeck rose very sharply while the market rose slightly.
The move was very big for Lundbeck, rare in the past year.
The share price is near its highest close of the past year.
+9.00% market +0.86% Lundbeck rose very sharply over the last five trading days, a much bigger move than the market's slight gain. Read →
Lundbeck rose very sharply over the last five trading days, a much bigger move than the market's slight gain.
Such a large move for Lundbeck is rare, happening only once in the past year.
The main driver was likely the board change: former Novo Nordisk CEO Lars Fruergaard Jørgensen is set to become chair of the board, which investors seem to welcome.
Analysts also raised their price targets, meaning the fair share price they estimate, after new Parkinson's trial data.
+4.00% market +0.06% Lundbeck rose very sharply, with no company news from that day explaining it. Read →
Lundbeck rose very sharply, with no company news from that day explaining it.
Over the same day OMX Copenhagen 25 was roughly flat, so the stock moved on its own.
The move was very big for Lundbeck, about five times a normal day, and trading was well above its usual level.
Over the last five trading days the stock rose very sharply, far more than the market.
Likely reasons include the analyst upgrades earlier in the week, including BNP Paribas raising its fair value estimate, and the board change announcing former Novo Nordisk CEO Lars Fruergaard Jørgensen as the next chair.
+1.56% market +1.87% Lundbeck rose clearly, with no company news explaining it. Read →
Lundbeck rose clearly, with no company news explaining it.
The market also rose sharply that day, so the move was in line with OMX Copenhagen 25.
Over the last five trading days the stock rose sharply, alongside the wider market.
Trading was about twice a normal day's volume, and the share price is near its highest level of the past year.
The most likely drivers are the broad market rally and renewed interest after the board change announced last week.
+3.39% market −0.08% Lundbeck jumped sharply, while the wider market stayed flat. Read →
Lundbeck jumped sharply, while the wider market stayed flat.
The move was very big for Lundbeck and trading was heavy, about twice normal.
The most likely reason is the board news: analysts see Fruergaard Jørgensen, a former Novo Nordisk chief executive, lifting Lundbeck, though the owner foundation could limit the gain.
Over the last five trading days Lundbeck rose clearly, a big move for it, while the market was roughly unchanged.
Next, Lundbeck reports earnings on 11 November 2026.
Learn more · Why do stocks move on earnings day? · Why do stocks go up and down?